News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
AstraZeneca Sees First Merck & Co., Inc. Payment Capped At $3.3 Billion
March 14, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, March 14 (Reuters) - AstraZeneca Plc said on Tuesday it believed the first option payment due to Merck & Co Inc in 2008 under a complex marketing partnership scheme between the firms was unlikely to exceed a net $3.3 billion.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
AstraZeneca
Merck & Co.
MORE ON THIS TOPIC
Layoff Tracker
Gilead laying off vast majority of Arcellx employees
May 8, 2026
·
51 min read
·
BioSpace Editorial Staff
Earnings
Gilead sets blockbuster bar for Yeztugo’s first full year on the market
May 8, 2026
·
2 min read
·
Tristan Manalac
Pipeline
Ascendis retreats to rare endocrinology wheelhouse as cancer plans falter
May 8, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
FDA pilots AI-informed one-day facility inspections
May 7, 2026
·
2 min read
·
Nick Paul Taylor